Wells Fargo sees downside to Amgen’s (AMGN) 2025 consensus estimates, saying the company’ sales guidance could came in below expectations. It ...

Amgen Inc (AMGN) stock saw a modest uptick, ending the day at $272.11 which represents a slight increase of $2.68 or 0.99% from the prior close of $269.43. The stock opened at $276.97 and touched a ...

Arcus Biosciences named former Amgen executive Richard Markus as its chief medical officer. The biopharmaceutical company, which is focused on cancer treatments, said Tuesday that Markus is scheduled ...

Amgen AMGN announced that the FDA has approved its KRAS inhibitor, Lumakras (sotorasib), in combination with its anti-EGFR ...

Amgen's dividend profile shines, but growth slows. See why AMGN stock faces regulatory risks and offers limited incentives ...

Approval is based on data from the Phase III CodeBreaK 300 trial, which demonstrated that treatment with Lumakras and ...

Amgen’s Lumakras and AstraZeneca’s Calquence are both in line to expand their respective oncology reaches with new FDA ...

Amgen has announced a $1 billion expansion in Holly Springs and has signed a dozen students from Wake Technical Community ...

Amgen Inc. closed $79.75 short of its 52-week high ($346.85), which the company achieved on July 25th.

Today, Benzinga's options scanner spotted 11 options trades for Amgen. This isn't normal. The overall sentiment of these ...

High-yield dividend stocks may not appeal to some investors. However, if you're among those investors looking for income, ...

Analyst Evan Seigerman of BMO Capital maintained a Buy rating on Amgen (AMGN – Research Report), retaining the price target of $362.00.Stay ...